Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
07:45am, Friday, 18'th Oct 2024
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
11:07am, Thursday, 17'th Oct 2024
On Thursday, Amicus Therapeutics FOLD announced that it has entered into a License Agreement with Teva Pharmaceuticals Inc. TEVA.
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
07:00am, Thursday, 17'th Oct 2024
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
07:00am, Friday, 04'th Oct 2024
PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the
'Boring' Amicus Therapeutics Is Making Progress
02:44am, Sunday, 29'th Sep 2024
Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is m
3 'Repeatable' Biotech Trades
12:46pm, Wednesday, 25'th Sep 2024
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churnin
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
07:46am, Tuesday, 03'rd Sep 2024
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
07:05am, Tuesday, 03'rd Sep 2024
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
07:00am, Friday, 30'th Aug 2024
PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
12:26pm, Wednesday, 21'st Aug 2024
Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales.
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
10:28pm, Thursday, 15'th Aug 2024
Amicus Therapeutics focuses on rare diseases like Fabry and Pompe, with Galafold and Pombiliti as main value drivers. Galafold is the only oral treatment for Fabry disease, stabilizing the alpha-Gal A
5 Stocks Under $10 Growing 50% Or More
10:13am, Sunday, 11'th Aug 2024
Are you looking for low-cost stocks to add to your portfolio?
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
11:36am, Friday, 09'th Aug 2024
Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:02pm, Thursday, 08'th Aug 2024
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Stre
Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates
09:26am, Thursday, 08'th Aug 2024
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago.
